AbCellera Biologics Azioni (NASDAQ: ABCL)

AbCellera Biologics (NASDAQ:ABCL) Azioni

AbCellera Biologics

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Inc

WIIM

Ethan Allen Interiors shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, Telsey Advisory Group cut its price target on the stock from $32 to $30.

Shares of Hyperscale Data Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NASDAQ">GPUS</a>) soared over <a href="https://www.benzinga.com/25/05/45202027/hyperscale-data-stock-soars-on-preliminary-q1-and-fy25-guidance">400% on Monday</a> after the company reported preliminary financial results for first-quarter 2025, with revenue surpassing $25 million. On Tuesday, the stock retreated 24% to $5.88, likely on profit-taking.
What To Know: The company also <a href="https://www.benzinga.com/pressreleases/25/05/g45189872/hyperscale-data-announces-preliminary-25-million-in-revenue-for-q1-2025-provides-full-year-guidanc">issued</a> bullish full-year guidance, projecting revenue between $115 million and $125 million, citing year-over-year growth across subsidiaries including Ault Global Real Estate Equities, Circle 8 Crane Services and TurnOnGreen.
A key driver of first-quarter performance was a one-time $9.7 million gain tied to the deconsolidation of Avalanche International. In a strategic move, Hyperscale is also converting its Michigan data center into a next-generation AI facility, aiming to capture growth in the booming AI infrastructure sector.
CEO William B. Horne emphasized the company's focus on high-growth areas and streamlining operations via non-core asset divestitures.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45220645/us-trade-deficit-soars-to-record-140b-as-imports-rocket-ahead-of-trumps-tariffs">US Trade Deficit Soars To Record $140B As Imports Rocket Ahead Of Trump&#8217;s Tariffs</a>
<h2 class="wp-block-heading">How To Buy GPUS Stock</h2>
By now you're likely curious about how to participate in the market for Hyperscale Data &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Hyperscale Data, which is trading at $4.94 as of publishing time, $100 would buy you 20.24 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, GPUS has a 52-week high of $20.26 and a 52-week low of $1.23.

News

GPUS

Hyperscale Data (GPUS) Stock Falls After 400% Rally: What's Going On?

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Amphastar Pharma will report an earnings per share (EPS) of $0.69.
Investors in Amphastar Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.02 in the last quarter, leading to a 9.72% drop in the share price on the following day.
Here's a look at Amphastar Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.94</td>
<td>0.99</td>
<td>0.77</td>
<td>0.74</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.92</td>
<td>0.96</td>
<td>0.94</td>
<td>1.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>-14.000000000000002%</td>
<td>13.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543855_0.png" alt="eps graph" />
<h3>Amphastar Pharma Share Price Analysis</h3>
Shares of Amphastar Pharma were trading at $25.12 as of May 05. Over the last 52-week period, shares are down 41.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Amphastar Pharma</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Amphastar Pharma.
Analysts have given Amphastar Pharma a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $32.0, indicating a potential 27.39% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Innoviva, Pacira BioSciences and Ocular Therapeutix, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Innoviva, with an average 1-year price target of $55.0, suggesting a potential 118.95% upside.</li>
<li>Analysts currently favor an Buy trajectory for Pacira BioSciences, with an average 1-year price target of $44.6, suggesting a potential 77.55% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ocular Therapeutix, with an average 1-year price target of $15.83, suggesting a potential 36.98% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Innoviva, Pacira BioSciences and Ocular Therapeutix, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphastar Pharma</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$86.65M</td>
<td>5.20%</td>
</tr>
<tr>
<td>Innoviva</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$84.64M</td>
<td>2.99%</td>
</tr>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>3.32%</td>
<td>$147.37M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Ocular Therapeutix</td>
<td>Buy</td>
<td>15.41%</td>
<td>$15.85M</td>
<td>-14.50%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Amphastar Pharma ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the top. The consensus rating for Amphastar Pharma is Neutral.
<h3>Delving into Amphastar Pharma's Background</h3>
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
<h3>Understanding the Numbers: Amphastar Pharma's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Amphastar Pharma's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 4.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amphastar Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amphastar Pharma's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.43%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.89, Amphastar Pharma adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/AMPH/earnings">To track all earnings releases for Amphastar Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AMPH

Earnings Outlook For Amphastar Pharma

Sabre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Sabre will report an earnings per share (EPS) of $0.01.
Anticipation surrounds Sabre's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 8.92% increase in the share price on the following day.
Here's a look at Sabre's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.10</td>
<td>-0.03</td>
<td>-0.08</td>
<td>-0.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543828_0.png" alt="eps graph" />
<h3>Market Performance of Sabre's Stock</h3>
Shares of Sabre were trading at $2.53 as of May 05. Over the last 52-week period, shares are down 2.84%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/SABR/earnings">To track all earnings releases for Sabre visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SABR

Examining the Future: Sabre's Earnings Outlook

Niagen Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Niagen Bioscience to report an earnings per share (EPS) of $0.02.
The announcement from Niagen Bioscience is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.07, which was followed by a 52.68% increase in the share price the next day.
Here's a look at Niagen Bioscience's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.02</td>
<td>0</td>
<td>-0.02</td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.09</td>
<td>0.02</td>
<td>0</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>53.0%</td>
<td>68.0%</td>
<td>10.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543817_0.png" alt="eps graph" />
<h3>Niagen Bioscience Share Price Analysis</h3>
Shares of Niagen Bioscience were trading at $8.45 as of May 05. Over the last 52-week period, shares are up 120.1%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Take on Niagen Bioscience</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Niagen Bioscience.
A total of 2 analyst ratings have been received for Niagen Bioscience, with the consensus rating being Buy. The average one-year price target stands at $11.0, suggesting a potential 30.18% upside.
<h3>Comparing Ratings with Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of 10x Genomics, Azenta and Adaptive Biotechnologies, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for 10x Genomics, with an average 1-year price target of $16.36, suggesting a potential 93.61% upside.</li>
<li>Analysts currently favor an Buy trajectory for Azenta, with an average 1-year price target of $55.5, suggesting a potential 556.8% upside.</li>
<li>Analysts currently favor an Buy trajectory for Adaptive Biotechnologies, with an average 1-year price target of $10.2, suggesting a potential 20.71% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for 10x Genomics, Azenta and Adaptive Biotechnologies, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niagen Bioscience</td>
<td>Buy</td>
<td>37.41%</td>
<td>$18.20M</td>
<td>17.84%</td>
</tr>
<tr>
<td>10x Genomics</td>
<td>Buy</td>
<td>-10.30%</td>
<td>$110.95M</td>
<td>-6.84%</td>
</tr>
<tr>
<td>Azenta</td>
<td>Buy</td>
<td>4.08%</td>
<td>$68.67M</td>
<td>-0.76%</td>
</tr>
<tr>
<td>Adaptive Biotechnologies</td>
<td>Buy</td>
<td>25.24%</td>
<td>$35.46M</td>
<td>-15.19%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Niagen Bioscience ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom compared to its peers.
<h3>About Niagen Bioscience</h3>
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
<h3>Niagen Bioscience: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Niagen Bioscience showcased positive performance, achieving a revenue growth rate of 37.41% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Niagen Bioscience's net margin is impressive, surpassing industry averages. With a net margin of 24.65%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Niagen Bioscience's ROE stands out, surpassing industry averages. With an impressive ROE of 17.84%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Niagen Bioscience's ROA stands out, surpassing industry averages. With an impressive ROA of 11.5%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Niagen Bioscience adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/NAGE/earnings">To track all earnings releases for Niagen Bioscience visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NAGE

What's Next: Niagen Bioscience's Earnings Preview

Limbach Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance with its midpoint above estimates.

Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Allient to report an earnings per share (EPS) of $0.34.
The market awaits Allient's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.06, leading to a 6.61% increase in the share price the following trading session.
Here's a look at Allient's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.25</td>
<td>0.23</td>
<td>0.42</td>
<td>0.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.31</td>
<td>0.31</td>
<td>0.29</td>
<td>0.58</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>7.000000000000001%</td>
<td>-14.000000000000002%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543795_0.png" alt="eps graph" />
<h3>Tracking Allient's Stock Performance</h3>
Shares of Allient were trading at $21.74 as of May 05. Over the last 52-week period, shares are down 29.55%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Allient</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Allient.
Analysts have provided Allient with 1 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $35.0, suggesting a potential 60.99% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of KULR Tech Gr, Amprius Technologies and LSI Industries, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for KULR Tech Gr, with an average 1-year price target of $5.0, suggesting a potential 77.0% downside.</li>
<li>Analysts currently favor an Buy trajectory for Amprius Technologies, with an average 1-year price target of $9.25, suggesting a potential 57.45% downside.</li>
<li>Analysts currently favor an Buy trajectory for LSI Industries, with an average 1-year price target of $26.0, suggesting a potential 19.6% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
In the peer analysis summary, key metrics for KULR Tech Gr, Amprius Technologies and LSI Industries are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allient</td>
<td>Outperform</td>
<td>-13.47%</td>
<td>$38.37M</td>
<td>1.12%</td>
</tr>
<tr>
<td>KULR Tech Gr</td>
<td>Buy</td>
<td>44.42%</td>
<td>$2.14M</td>
<td>-14.76%</td>
</tr>
<tr>
<td>Amprius Technologies</td>
<td>Buy</td>
<td>172.43%</td>
<td>$-2.85M</td>
<td>-19.36%</td>
</tr>
<tr>
<td>LSI Industries</td>
<td>Buy</td>
<td>-10.32%</td>
<td>$34.86M</td>
<td>1.77%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Allient ranks at the bottom for Revenue Growth among its peers. It is at the top for Gross Profit. Allient is at the bottom for Return on Equity.
<h3>Delving into Allient's Background</h3>
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty motion control components and systems. The firm primarily caters to the vehicle, medical, aerospace and defense, and electronics and industrial, pumps, and robotics sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
<h3>Financial Insights: Allient</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Allient faced challenges, resulting in a decline of approximately -13.47% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Allient's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.47%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Allient's ROE excels beyond industry benchmarks, reaching 1.12%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Allient's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.51% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.94, Allient faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/ALNT/earnings">To track all earnings releases for Allient visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNT

A Look Ahead: Allient's Earnings Forecast

BWS Financial analyst Hamed Khorsand maintains Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) with a Buy and maintains $18 price target.

Price Target

Analyst Ratings

ADEA

BWS Financial Maintains Buy on Adeia, Maintains $18 Price Target

Centrus Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Centrus Energy to report an earnings per share (EPS) of $-0.08.
Investors in Centrus Energy are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $1.56 in the last quarter, leading to a 33.13% increase in the share price on the following day.
Here's a look at Centrus Energy's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.64</td>
<td>0.22</td>
<td>0.78</td>
<td>0.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.20</td>
<td>-0.30</td>
<td>1.89</td>
<td>-0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>33.0%</td>
<td>12.0%</td>
<td>17.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543777_0.png" alt="eps graph" />
<h3>Centrus Energy Share Price Analysis</h3>
Shares of Centrus Energy were trading at $71.66 as of May 05. Over the last 52-week period, shares are up 72.49%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Centrus Energy</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Centrus Energy.
A total of 3 analyst ratings have been received for Centrus Energy, with the consensus rating being Buy. The average one-year price target stands at $177.67, suggesting a potential 147.93% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Peabody Energy, Hallador Energy and Alliance Res Partners, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Peabody Energy, with an average 1-year price target of $22.5, suggesting a potential 68.6% downside.</li>
<li>Analysts currently favor an Buy trajectory for Hallador Energy, with an average 1-year price target of $15.0, suggesting a potential 79.07% downside.</li>
<li>Analysts currently favor an Buy trajectory for Alliance Res Partners, with an average 1-year price target of $29.0, suggesting a potential 59.53% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Peabody Energy, Hallador Energy and Alliance Res Partners, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centrus Energy</td>
<td>Buy</td>
<td>46.33%</td>
<td>$61.80M</td>
<td>45.16%</td>
</tr>
<tr>
<td>Peabody Energy</td>
<td>Buy</td>
<td>-9.06%</td>
<td>$166.10M</td>
<td>0.84%</td>
</tr>
<tr>
<td>Hallador Energy</td>
<td>Buy</td>
<td>-21.21%</td>
<td>$61.71M</td>
<td>-102.01%</td>
</tr>
<tr>
<td>Alliance Res Partners</td>
<td>Buy</td>
<td>-8.41%</td>
<td>$64.13M</td>
<td>4.06%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Centrus Energy ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity compared to its peers.
<h3>All You Need to Know About Centrus Energy</h3>
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
<h3>Centrus Energy: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centrus Energy's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 46.33%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 35.42%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Centrus Energy's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 45.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Centrus Energy's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.38%, the company showcases efficient use of assets and strong financial health.
Debt Management: Centrus Energy's debt-to-equity ratio surpasses industry norms, standing at 0.97. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/LEU/earnings">To track all earnings releases for Centrus Energy visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Centrus Energy

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.penguinsolutions.com%2F&amp;esheet=54249532&amp;newsitemid=20250506240164&amp;lan=en-US&amp;anchor=Penguin+Solutions&amp;index=1&amp;md5=b59fead34143067c373a5cc6bc110713">Penguin Solutions</a>, Inc.(Penguin Solutions, Nasdaq: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.smartm.com%2Fstock-information%2Fstock-quote-and-charts%2Fdefault.aspx&amp;esheet=54249532&amp;newsitemid=20250506240164&amp;lan=en-US&amp;anchor=PENG&amp;index=2&amp;md5=a2c08bd6fa416298eab7c9ee0c4caa0b">PENG</a>) today announced a new strategic agreement with CDW, which will make the full portfolio of Penguin Solutions' AI infrastructure offerings available to CDW's customer base. Penguin Solutions' <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.penguinsolutions.com%2Fsolutions%2Fai%2Foriginai&amp;esheet=54249532&amp;newsitemid=20250506240164&amp;lan=en-US&amp;anchor=OriginAI%26%23174%3B+factory+infrastructure+solution&amp;index=3&amp;md5=e43f534f522f3f9d9183232165929222">OriginAI&#xAE; factory infrastructure solution</a> and its unique set of management software tools and services provide the foundation to design, build, deploy and manage GPU clusters and drive AI success for companies of any size in any industry.

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions Signs Strategic Agreement With CDW To Make Full Portfolio Of Penguin Solutions' AI Infrastructure Offerings Available To CDW's Customer Base

Ferroglobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSM#NASDAQ">GSM</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Ferroglobe to report an earnings per share (EPS) of $0.05.
Investors in Ferroglobe are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.04, leading to a 4.97% drop in the share price on the subsequent day.
Here's a look at Ferroglobe's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>0.16</td>
<td>0.05</td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.03</td>
<td>0.11</td>
<td>0.13</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-7.000000000000001%</td>
<td>2.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543762_0.png" alt="eps graph" />
<h3>Performance of Ferroglobe Shares</h3>
Shares of Ferroglobe were trading at $3.485 as of May 05. Over the last 52-week period, shares are down 35.73%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GSM/earnings">To track all earnings releases for Ferroglobe visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Ferroglobe's Earnings Outlook

Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Marriott Vacations to report an earnings per share (EPS) of $1.43.
The market awaits Marriott Vacations's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.34 in the last quarter, leading to a 9.26% drop in the share price on the following day.
Here's a look at Marriott Vacations's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.52</td>
<td>1.57</td>
<td>2.03</td>
<td>1.69</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.86</td>
<td>1.80</td>
<td>1.10</td>
<td>1.80</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>13.0%</td>
<td>-8.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543752_0.png" alt="eps graph" />
<h3>Market Performance of Marriott Vacations's Stock</h3>
Shares of Marriott Vacations were trading at $58.48 as of May 05. Over the last 52-week period, shares are down 39.39%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/VAC/earnings">To track all earnings releases for Marriott Vacations visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Marriott Vacations's Earnings Expectations

On May 5, Gwynne Shotwell, Board Member at Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: In a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0000931015/000162828025022248//Archives/edgar/data/931015/000162828025022248/0001628280-25-022248-index.htm">U.S. Securities and Exchange Commission</a>, it was disclosed that Shotwell bought 4,320 shares of Polaris, amounting to a total of $149,990.
Tracking the Tuesday's morning session, Polaris shares are trading at $33.31, showing a down of 1.8%.
<h3>All You Need to Know About Polaris</h3>
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
<h3>Polaris: A Financial Overview</h3>
Revenue Growth: Polaris's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -11.55%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 15.95%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Polaris exhibits below-average bottom-line performance with a current EPS of -1.17.
</li>
</ul>
Debt Management: Polaris's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.78, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 47.77 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.28 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Polaris's EV/EBITDA ratio, lower than industry averages at 7.6, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000931015">Check Out The Full List Of Polaris's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Major Purchase Alert: Gwynne Shotwell Invests $149K In Polaris Stock

A significant insider buy by Gary Hendrickson, Board Member at Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>), was executed on May 5, and reported in the recent SEC filing.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000931015/000162828025022249//Archives/edgar/data/931015/000162828025022249/0001628280-25-022249-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Hendrickson increased their investment in Polaris by purchasing 4,320 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $149,990.
Polaris shares are trading up 0.99% at $34.26 at the time of this writing on Tuesday morning.
<h3>About Polaris</h3>
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
<h3>Financial Insights: Polaris</h3>
Revenue Challenges: Polaris's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -11.55%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 15.95%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Polaris's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -1.17.
</li>
</ul>
Debt Management: Polaris's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.78, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 47.77 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.28 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Polaris's EV/EBITDA ratio at 7.6 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000931015">Check Out The Full List Of Polaris's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Gary Hendrickson Boosts Confidence With $149K Purchase Of Polaris Stock

It was revealed in a recent SEC filing that Darryl Jackson, Board Member at Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) made a noteworthy insider purchase on May 5,.
What Happened: Jackson's recent move, as outlined in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000931015/000162828025022250//Archives/edgar/data/931015/000162828025022250/0001628280-25-022250-index.htm">U.S. Securities and Exchange Commission</a> on Monday, involves purchasing 4,320 shares of Polaris. The total transaction value is $149,990.
Polaris shares are trading up 0.99% at $34.26 at the time of this writing on Tuesday morning.
<h3>Delving into Polaris's Background</h3>
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
<h3>Financial Milestones: Polaris's Journey</h3>
Revenue Challenges: Polaris's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -11.55%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 15.95%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Polaris's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of -1.17.
</li>
</ul>
Debt Management: Polaris's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.78, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Polaris's current Price to Earnings (P/E) ratio of 47.77 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.28 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Polaris's EV/EBITDA ratio, lower than industry averages at 7.6, indicates attractively priced shares.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000931015">Check Out The Full List Of Polaris's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member Of Polaris Purchased $149K In Stock

OFIX

Orthofix Medical shares are trading lower after the company cut its FY25 sales guidance below estimates.

On May 5, Lawrence Kingsley, Board Member at Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000931015/000162828025022251//Archives/edgar/data/931015/000162828025022251/0001628280-25-022251-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled that Kingsley made a notable purchase of 4,320 shares of Polaris, valuing at $149,990.
Polaris shares are trading up 0.99% at $34.26 at the time of this writing on Tuesday morning.
<h3>About Polaris</h3>
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
<h3>Financial Insights: Polaris</h3>
Decline in Revenue: Over the 3 months period, Polaris faced challenges, resulting in a decline of approximately -11.55% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 15.95%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Polaris's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -1.17.
</li>
</ul>
Debt Management: Polaris's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.78, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 47.77, Polaris's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.28 is lower than the industry average, implying a discounted valuation for Polaris's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 7.6 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000931015">Check Out The Full List Of Polaris's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

149K Reasons To Be Bullish On Polaris Stock

Azenta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.
Analysts estimate that Azenta will report an earnings per share (EPS) of $0.08. 
The market awaits Azenta's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 0.52% increase in the share price on the following day.
Here's a look at Azenta's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>0.10</td>
<td>0.08</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.18</td>
<td>0.16</td>
<td>0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-3.0%</td>
<td>-9.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543733_0.png" alt="eps graph" />
<h3>Market Performance of Azenta's Stock</h3>
Shares of Azenta were trading at $26.2 as of May 05. Over the last 52-week period, shares are down 52.28%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analysts' Take on Azenta</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Azenta.
Analysts have given Azenta a total of 2 ratings, with the consensus rating being Buy. The average one-year price target is $55.5, indicating a potential 111.83% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of 10x Genomics, Adaptive Biotechnologies and Niagen Bioscience, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for 10x Genomics, with an average 1-year price target of $16.36, suggesting a potential 37.56% downside.</li>
<li>Analysts currently favor an Buy trajectory for Adaptive Biotechnologies, with an average 1-year price target of $10.2, suggesting a potential 61.07% downside.</li>
<li>Analysts currently favor an Buy trajectory for Niagen Bioscience, with an average 1-year price target of $11.0, suggesting a potential 58.02% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for 10x Genomics, Adaptive Biotechnologies and Niagen Bioscience, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azenta</td>
<td>Buy</td>
<td>4.08%</td>
<td>$68.67M</td>
<td>-0.76%</td>
</tr>
<tr>
<td>10x Genomics</td>
<td>Buy</td>
<td>-10.30%</td>
<td>$110.95M</td>
<td>-6.84%</td>
</tr>
<tr>
<td>Adaptive Biotechnologies</td>
<td>Buy</td>
<td>25.24%</td>
<td>$35.46M</td>
<td>-15.19%</td>
</tr>
<tr>
<td>Niagen Bioscience</td>
<td>Buy</td>
<td>37.41%</td>
<td>$18.20M</td>
<td>17.84%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Azenta ranks first in revenue growth among its peers. It has the highest gross profit margin. However, it has the lowest return on equity.
<h3>Discovering Azenta: A Closer Look</h3>
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
<h3>Azenta: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Azenta's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 4.08%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Azenta's net margin is impressive, surpassing industry averages. With a net margin of -9.04%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Azenta's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.76%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Azenta's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.64%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Azenta's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<a href="https://www.benzinga.com/quote/AZTA/earnings">To track all earnings releases for Azenta visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTA

Insights Ahead: Azenta's Quarterly Earnings

George Bilicic, Director at Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>), disclosed an insider purchase on May 5, based on a new SEC filing.
What Happened: Bilicic demonstrated confidence in Polaris by purchasing 4,320 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000931015/000162828025022252//Archives/edgar/data/931015/000162828025022252/0001628280-25-022252-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value of the transaction is $149,990.
Tracking the Tuesday's morning session, Polaris shares are trading at $34.26, showing a up of 0.99%.
<h3>Discovering Polaris: A Closer Look</h3>
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
<h3>Polaris: Financial Performance Dissected</h3>
Decline in Revenue: Over the 3 months period, Polaris faced challenges, resulting in a decline of approximately -11.55% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 15.95%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Polaris's EPS is below the industry average. The company faced challenges with a current EPS of -1.17. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Polaris's debt-to-equity ratio stands notably higher than the industry average, reaching 1.78. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 47.77 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.28 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 7.6, Polaris presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000931015">Check Out The Full List Of Polaris's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Major Purchase Alert: George Bilicic Invests $149K In Polaris Stock

A notable insider purchase on May 5, was reported by KEVIN FARR, Director at Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>), based on the most recent SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000931015/000162828025022254//Archives/edgar/data/931015/000162828025022254/0001628280-25-022254-index.htm">U.S. Securities and Exchange Commission</a> on Monday, FARR purchased 4,320 shares of Polaris, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $149,990.
As of Tuesday morning, Polaris shares are down by 1.8%, currently priced at $33.31.
<h3>Get to Know Polaris Better</h3>
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
<h3>Polaris's Economic Impact: An Analysis</h3>
Revenue Challenges: Polaris's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -11.55%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 15.95%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Polaris's EPS reflects a decline, falling below the industry average with a current EPS of -1.17.
</li>
</ul>
Debt Management: Polaris's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.78, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 47.77, Polaris's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.28, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 7.6, Polaris presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000931015">Check Out The Full List Of Polaris's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Noteworthy Insider Activity: KEVIN FARR Invests $149K In Polaris Stock

Press Releases

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera Reports Full Year 2024 Business Results

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

ABBV

ABCL

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

AbCellera Biologics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO